Kratom Dependence and the DEA's 7-OH Scheduling: What Changing Access Means for Treatment

Why it matters

When regulated products disappear from shelves, people with physical dependence face real withdrawal risk — and may turn to unregulated sources or other substances. This analysis explains what clinicians and treatment providers need to know as the 7-OH scheduling order takes effect.

The big picture

The DEA's July 2026 announcement targets concentrated 7-OH and three related substances above specified concentration thresholds. The kratom plant itself is not scheduled. For the estimated millions of Americans who use kratom or 7-OH products regularly, abrupt loss of access can trigger withdrawal symptoms similar to opioid withdrawal. Research on kratom use disorder treatment is still developing — no randomized controlled trials have directly evaluated methadone or buprenorphine specifically for kratom dependence, though case reports show promise for medications used in opioid use disorder.

Key findings

• DEA's July 1, 2026 action targets 7-OH above 0.05% concentration in plant material and 0.05% or 1mg in processed products; the kratom plant itself is not scheduled
• Three related synthetic substances also scheduled: mitragynine pseudoindoxyl (MP), MGM-15, and MGM-16
• Withdrawal symptoms from 7-OH dependence include irritability, anxiety, restlessness, muscle aches, sleep disruption, sweating, nausea, and cravings
• No RCTs currently exist specifically evaluating buprenorphine or methadone for kratom use disorder; clinical evidence comes primarily from case reports and case series
• People with dependence should not stop abruptly; consulting a substance use provider before stopping is recommended

What they say

The center advises: "Do not assume that you need to stop abruptly simply because regulations are changing. If you are physically dependent, suddenly stopping can result in withdrawal. Instead, consider talking with a healthcare or substance use professional about your individual situation."

Bottom line

As concentrated 7-OH products face federal scheduling, individuals who have developed physical dependence need access to substance use treatment — not just product removal — to avoid dangerous abrupt withdrawal.